CAMBRIDGE, Mass., Aug. 31 /PRNewswire/ -- ETEX is pleased to announce
the promotion of Dr. Aliassghar Tofighi to the position of Distinguished
Research Fellow. In this role, Dr. Tofighi will apply his extensive
scientific expertise to further the discovery and exploration of potential
inventions and products relevant to ETEX's technology. Dr. Tofighi also
will be responsible for expanding ETEX's scientific presence in
organizations and publications related to bioceramics and bone repair.
    Dr. Tofighi completed his first Doctorate in Material Physics in 1976
at the Calcium Phosphate Research Center (CPRC) in Toulouse, France,
followed by a Ph.D. in Material Science specializing in High Temperature
Refractory Ceramics from the Institut National Polytechnique de Toulouse
(France) in 1982. Dr. Tofighi served as a Professor of Physical Chemistry
at Ecole National Superieur Travaux Public in West Africa, becoming
Director of the Science department in 1985. In 1992, Dr. Tofighi returned
to Toulouse's CPRC to lead studies in bioceramics and calcium phosphate
bone cements, where he developed a new process regarding low temperature
ceramization of apatitic calcium phosphate.
    Dr. Tofighi joined ETEX in 1995 as a Senior Scientist; since that time,
he has held a variety of positions including Director of Process
Development, Director of Research, Director of Development, and V.P. of
Research & Development. During his career, he has been awarded 14 patents,
authored over 70 scientific publications, and has contributed chapters in
two scientific books. He has served as a review committee member for
Biomaterials Journal, the International Scientific Committee of Bioceramics
and ASTM.
    "ETEX is very pleased to have Dr. Ali Tofighi continue as a valued
member of our organization," said Wayne Mayhew, President and Chief
Executive Officer of ETEX. "Ali's new role will allow ETEX to utilize his
knowledge of biomaterial science and calcium phosphate to broaden the
musculoskeletal repair applications for our proprietary technology."
    Headquartered in Cambridge, Massachusetts, ETEX has its roots in
biomaterials research and has core expertise in the development and
manufacture of calcium phosphate materials for osteobiologic applications.
alpha-BSM(R) Bone Substitute Material is the first product to be
commercialized from ETEX's research portfolio. alpha-BSM(R) is distributed
in the United States, Canada and Australia for the treatment of bone voids
resulting from fractures and other medical conditions.
    For more information, please visit http://www.etexcorp.com.

    ETEX Corporation
    David Palagi
    Marketing Product Manager
    617-577-7270

Link to this page: